Online inquiry

IVTScrip™ mRNA-Human ADGRE2, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WK8937MR)

This product GTTS-WK8937MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the ADGRE2 protein. This product can be used in Monocyte-related researches.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Human
RefSeq NM_001271052.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification Chromatography
Target Gene
Gene ID 30817
UniProt ID Q9UHX3
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Human ADGRE2, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WK8937MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WK17720MR IVTScrip™ mRNA-Human AHCYL1, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA AHCYL1
GTTS-WK7920MR IVTScrip™ mRNA-Human ACD, (Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACD
GTTS-WK12504MR IVTScrip™ mRNA-Human ADAMTS5, (Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ADAMTS5
GTTS-WK25890MR IVTScrip™ mRNA-Human ARHGAP25, (Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ARHGAP25
GTTS-WK9712MR IVTScrip™ mRNA-Human ACAP2, (Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA ACAP2
GTTS-WK21205MR IVTScrip™ mRNA-Human ANKRD18DP, (Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ANKRD18DP
GTTS-WK7746MR IVTScrip™ mRNA-Human ADGRL2, (Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ADGRL2
GTTS-WK23183MR IVTScrip™ mRNA-Human ARHGAP15, (Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARHGAP15
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW